Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura

Hematology

Volumn 14, Issue 4, 2009, Pages 227-236

  Robak, T ^a   Salama, A ^b   Kovaleva, L ^c   Vyhovska, Y ^d   Davies, S V ^e   Mazzucconi, M G ^f   Zenker, O ^g   Kiessling, P ^g  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^d Institute of Blood Pathology and Transfusion Medicine AMS   (Ukraine)

^e TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g CSL BEHRING GMBH   (Germany)

Author keywords

Chronic immune thrombocytopenic purpura, liquid intravenous immunoglobulin, efficacy, safety

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; PRIVIGEN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTUSION; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; GINGIVA BLEEDING; HEMATOMA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MULTICENTER STUDY; NAUSEA; ORAL BLEEDING; PETECHIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SHELF LIFE; SKIN BLEEDING; THROMBOCYTE COUNT; TREATMENT RESPONSE; VOMITING; ADOLESCENT; BLOOD; CHILD; DRUG EFFECT; FEMALE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; PROSPECTIVE STUDY; THROMBOCYTE;

ADOLESCENT; ADULT; AGED; BLOOD PLATELETS; CHILD; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; YOUNG ADULT;

EID: 70349907813     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X439773     Document Type: Article

References (36)

1. Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 2006; 43(3 Suppl 5): S3-S10. (Pubitemid 43964952)
2. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008; 99(1): 4-13.
3. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346(13): 995-1008.
4. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005; 90(6): 829-832.
5. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88(1): 3-40.
6. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120(4): 574-596.
7. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981; 36(1): 81-86. (Pubitemid 11137811)
8. Wolf HH, Davies SV, Borte M et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003; 84(1): 45-53.
9. Colovic M, Dimitrijevic M, Sonnenburg C, Suvajdzic N, Donfrid M, Bogdanovic A. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 2003; 4(5): 358-362.
10. Bussel JB, Eldor A, Kelton JG et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004; 91(4): 771-778.
11. Bierling P, Godeau B. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura. Hum Immunol 2005; 66(4): 387-394. (Pubitemid 40615794)
12. Kurlander R, Coleman RE, Moore J, Gockerman J, Rosse W, Siegal R. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. Am J Med 1987; 83(4A): 17-24.
13. Schnorf J, Arnet B, Burek-Kozlowska A et al. Laboratory parameters measured during infusion of immunoglobulin preparations for intravenous use and related to tolerability. In: Kazatchkine MD, Morell A (eds). Intravenous immunoglobulin research and therapy. New York, London: The Parthenon Publishing Group, 1996; 312-313.
14. Bolli R, Spycher MO, Brü gger R, Wü st B, Gennari K. IgG-dimer formation in liquid immunoglobulin preparations is inhibited by nicotinamide and other amphiphilic compounds. J Autoimmun 1999; (Suppl 1): 96.
15. Kempf C, Stucki M, Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 2007; 35(1): 35-42.
16. Stucki M, Boschetti N, Schaefer W et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008; 36(4): 239-247.
17. Druml W, Heinzel G, Kleinberger G. Amino acid kinetics in patients with sepsis. Am J Clin Nutr 2001; 73(5): 908-913.
18. Bussel JB, Kuter DJ, George JN et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006; 355(16): 1672-1681.
19. Brenner B. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin. Clin Exp Rheumatol 1996; 14(Suppl 15): S115-S119.
20. Tarantino MD, Young G, Bertolone SJ et al. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 2006; 148(4): 489-494.
21. Newland AC, Burton I, Cavenagh JD et al. Vigam-S, a solvent/ detergent-treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura. Transfus Med 2001; 11(1): 37-44.
22. Scribner CL, Kapit RM, Phillips ET, Rickles NM. Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994; 121(4): 305-306.
23. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121(4): 259-262.
24. Al-Ghamdi H, Mustafa MM, Al-Fawaz I, Al-Dowaish A. Acute aseptic meningitis associated with administration of immunoglobulin in children: a case report and review of the literature. Ann Saudi Med 1999; 19(4): 362-364.
25. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion 1986; 26(5): 410-412.
26. Thomas MJ, Misbah SA, Chapel HM, Jones M, Elrington G, Newsom-Davis J. Hemolysis after high-dose intravenous Ig. Blood 1993; 82(12): 3789.
27. Daw Z, Padmore R, Neurath D et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48(8): 1598-1601.
28. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106(7): 2244-2251.
29. George JN, Raskob GE, Vesely SK et al. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 2003; 74(3): 161-169.
30. Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112(4): 1076-1078.
31. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100(2): 728-730.
32. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003; 28(3): 249-255.
33. Nimmerjahn F, Ravetch JV. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007; 204(1): 11-15.
34. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345(10): 747-755.
35. Semple JW, Milev Y, Cosgrave D et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87(10): 4245-4254.
36. Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 2003; 92(6): 1206-1215.